Drug Profile
Bardoxolone methyl - Biogen
Alternative Names: Bard - Biogen; Bardoxolone methyl - Abbott/Kyowa Hakko Kirin/Biogen; CDDO-Me; NSC-713200; RTA-402Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
- Developer Biogen; Kyowa Kirin; University of Texas M. D. Anderson Cancer Center
- Class Anti-inflammatories; Antihypertensives; Antineoplastics; Antivirals; Carboxylic acids; Hepatoprotectants; Nitriles; Obesity therapies; Small molecules; Triterpenes; Urologics
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autosomal dominant polycystic kidney disease; COVID 2019 infections; Diabetic nephropathies; Haematological malignancies; Hereditary nephritis; Liver disorders; Malignant melanoma; Non-alcoholic steatohepatitis; Obesity; Pancreatic cancer; Pulmonary arterial hypertension; Pulmonary hypertension; Renal failure; Solid tumours; Viral hepatitis
Most Recent Events
- 26 Sep 2023 Reata Pharmaceuticals has been acquired and merged into Biogen
- 05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in Australia (PO)
- 05 Jun 2023 Discontinued - Phase-III for Renal failure (In adolescents, In children, In the elderly, In adults) in France (PO)